Avita Medical (RCEL) Expected to Announce Earnings on Thursday

Key Points

• Avita Medical to report Q1 2026 earnings after market close on Thursday, May 14 (call at 4:30 PM ET); analysts expect a loss of ($0.35) per share and revenue of $18.30 million.
• Shares trading near $4.42 (market cap ~ $136 million) and were up about 4.2%; the 12‑month range is $3.22–$9.85 with 50‑ and 200‑day SMAs around $4.49 and $4.04, respectively.
• Analyst sentiment is mixed with a consensus "Hold" and an average price target of $6.63, as ratings range from strong sell to outperform (some price targets as high as $10).

Avita Medical (NASDAQ:RCEL - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Avita Medical to post earnings of ($0.35) per share and revenue of $18.2960 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

Avita Medical Stock Up 4.2%

NASDAQ RCEL opened at $4.42 on Thursday. The company has a market capitalization of $136.05 million, a price-to-earnings ratio of -2.53 and a beta of 1.90. Avita Medical has a twelve month low of $3.22 and a twelve month high of $9.85. The stock has a fifty day simple moving average of $4.49 and a 200 day simple moving average of $4.04.

Analysts Set New Price Targets

A number of analysts recently weighed in on RCEL shares. Northland Securities started coverage on Avita Medical in a report on Thursday, March 5th. They issued an "outperform" rating and a $10.00 price objective for the company. Wall Street Zen downgraded Avita Medical from a "sell" rating to a "strong sell" rating in a report on Saturday, May 2nd. Weiss Ratings restated a "sell (e+)" rating on shares of Avita Medical in a report on Friday, March 27th. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Avita Medical in a report on Wednesday, April 8th. Finally, Lake Street Capital increased their price objective on Avita Medical from $3.00 to $3.50 and gave the company a "hold" rating in a report on Friday, January 16th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Avita Medical has a consensus rating of "Hold" and an average price target of $6.63.

Institutional Trading of Avita Medical

A number of institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its position in Avita Medical by 8.8% during the second quarter. Rhumbline Advisers now owns 42,168 shares of the company's stock valued at $223,000 after acquiring an additional 3,393 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Avita Medical by 122.2% during the fourth quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company's stock valued at $28,000 after acquiring an additional 4,425 shares during the last quarter. Deutsche Bank AG boosted its position in Avita Medical by 1,351.5% during the fourth quarter. Deutsche Bank AG now owns 7,896 shares of the company's stock valued at $27,000 after acquiring an additional 7,352 shares during the last quarter. Wells Fargo & Company MN boosted its position in Avita Medical by 98.5% during the fourth quarter. Wells Fargo & Company MN now owns 18,832 shares of the company's stock valued at $65,000 after acquiring an additional 9,345 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Avita Medical by 20.4% during the first quarter. Jane Street Group LLC now owns 63,744 shares of the company's stock valued at $519,000 after acquiring an additional 10,789 shares during the last quarter. Institutional investors own 27.66% of the company's stock.

Avita Medical Company Profile

Avita Medical, Inc NASDAQ: RCEL is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient's own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.